Pozelimab Clinical Trials
6 recruitingDrug
Phase 34Phase 41Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Regeneron Pharmaceuticals35 enrolled8 locationsNCT07154745
Recruiting
Phase 1
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Geographic Atrophy (GA)
Regeneron Pharmaceuticals54 enrolled5 locationsNCT07230834
Recruiting
Phase 4
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
CHAPLE Disease
Regeneron Pharmaceuticals5 enrolled1 locationNCT07142343
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Phase 3
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Regeneron Pharmaceuticals202 enrolled43 locationsNCT05744921
Recruiting
Phase 3
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Regeneron Pharmaceuticals190 enrolled69 locationsNCT05133531